{"id":"isotonic-sodium-chloride-0-9-percent","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperchloremic acidosis (with prolonged or excessive use)"},{"rate":null,"effect":"Fluid overload / Hypervolemia"},{"rate":null,"effect":"Hypokalemia (with chronic use without potassium supplementation)"},{"rate":null,"effect":"Local phlebitis at infusion site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This solution contains sodium and chloride ions in concentrations (0.9% w/v) that are isotonic with human blood plasma, preventing osmotic shifts across cell membranes. It is used for fluid replacement, electrolyte supplementation, and as a vehicle for drug administration. The solution does not exert a pharmacological effect but rather serves as a physiological support agent.","oneSentence":"Isotonic sodium chloride 0.9% restores and maintains fluid and electrolyte balance by providing a physiologically balanced saline solution that matches blood osmolarity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:22.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fluid and electrolyte replacement in dehydration"},{"name":"Vehicle for intravenous drug administration"},{"name":"Maintenance of vascular access patency"},{"name":"Perioperative fluid management"}]},"trialDetails":[{"nctId":"NCT05645107","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2022-12-26","conditions":"Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia","enrollment":386},{"nctId":"NCT07052513","phase":"PHASE2","title":"Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"M2RLAB SL","startDate":"2025-07-17","conditions":"Acute Kidney Injury","enrollment":98},{"nctId":"NCT05355974","phase":"PHASE3","title":"Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure","status":"COMPLETED","sponsor":"Wright State University","startDate":"2022-08-09","conditions":"Respiratory Failure, Hypotension and Shock, Hypotension on Induction","enrollment":42},{"nctId":"NCT02700828","phase":"PHASE2, PHASE3","title":"Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns","status":"COMPLETED","sponsor":"Semmelweis University","startDate":"2016-02","conditions":"Hypoxic-Ischemic Encephalopathy, Asphyxia","enrollment":32},{"nctId":"NCT02502903","phase":"PHASE1","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2015-07-13","conditions":"Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA)","enrollment":122},{"nctId":"NCT04006795","phase":"NA","title":"A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-08-28","conditions":"Skin Care","enrollment":40},{"nctId":"NCT04007159","phase":"NA","title":"To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-08-30","conditions":"Skin Care","enrollment":302},{"nctId":"NCT03306589","phase":"PHASE1","title":"Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-11","conditions":"Arthritis, Rheumatoid","enrollment":12},{"nctId":"NCT02085577","phase":"PHASE4","title":"The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-05","conditions":"Postoperative Pain, Chronic Pain, Analgesics","enrollment":147}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Isotonic saline"],"phase":"marketed","status":"active","brandName":"Isotonic sodium chloride 0.9 percent","genericName":"Isotonic sodium chloride 0.9 percent","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isotonic sodium chloride 0.9% restores and maintains fluid and electrolyte balance by providing a physiologically balanced saline solution that matches blood osmolarity. Used for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Maintenance of vascular access patency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}